Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise but have not been strong enough t

Trial Details

NCT ID

NCT06198296

Phase

PHASE1

Sponsor

Baylor College of Medicine

Status

RECRUITING

Cancer Type

Liposarcoma Sarcoma

Interventions

• 21.15.GPC3-CAR T cells

Locations (sample)

• Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

• Diagnosis of GPC3-positive\* solid tumors (as determined by immunohistochemistry with an extent score of \>=Grade 2 \[\>25% positive tumor cells\] …
• Age ≥21 years
• Lansky or Karnofsky score ≥60%
• Life expectancy ≥16 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →